ADA Scientific Sessions 2026 Abstract

The Efficacy of Dapagliflozin Is Heterogeneous across Different Etiologies of AKI and AKI-to-CKD Transition

By Yuan Wang, Yizhen Xu

Experiments in animalsInterventions

The paper

Yuan Wang, Yizhen Xu

Beijing

ADA Scientific Sessions 2026 Abstract, 5 Jun 2026

Presented at ADA Scientific Sessions 2026, poster 1376-P

doi.org/10.2337/db26-1376-p

Diabetes, Obesity & Metabolism4 Oct 2026
GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
The American Journal of Cardiology8 Oct 2026
Drug class linked to fewer deaths or complications in kidney disease
Clinical Journal of the American Society of Nephrology4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Clinical Pharmacology and Therapeutics4 Oct 2026
SGLT2 inhibitors raise genital but not urinary infection risk